MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neumora Therapeutics, Inc. - Common Stock (NQ:NMRA)

2.130 +0.090 (+4.41%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 771,124
Open 2.030
Bid (Size) 2.120 (400)
Ask (Size) 2.160 (500)
Prev. Close 2.040
Today's Range 2.020 - 2.200
52wk Range 0.6110 - 3.250
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
This Fund Put $3.4 Million Into Navan Despite a 60% Post-IPO Drop ↗
Navan delivers AI-powered travel and expense management software for enterprise clients seeking streamlined operations. 
Via The Motley Fool
Topics Artificial Intelligence Initial Public Offering Regulatory Compliance
News headline image
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
From Neumora Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+28.3%
+28.3%
1 Month
+19.7%
+19.7%
3 Month
-17.8%
-17.8%
6 Month
-2.7%
-2.7%
1 Year
+6.5%
+6.5%

More News

Read More
News headline image
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For August 6, 2025 ↗
Via Benzinga
News headline image
Top movers in Tuesday's pre-market session ↗
Via Chartmill
News headline image
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics to Participate in Upcoming Conferences in November
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Unusual volume stocks in Thursday's session ↗
Via Chartmill
News headline image
Unusual volume stocks in Wednesday's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies ↗
Via Stocktwits
News headline image
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
Neumora Therapeutics to Host Virtual R&D Day on October 27
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Warner Bros. Discovery Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
Via Benzinga
News headline image
Neumora Therapeutics to Participate in Upcoming Conferences in September
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
Neumora (NMRA) Q2 Loss Improves 10% ↗
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
Boston Beer Posts Better-Than-Expected Earnings, Joins Scholastic, Deckers Outdoor, Saia And Other Big Stocks Moving Higher On Friday ↗
Via Benzinga
News headline image
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
From Neumora Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Via Benzinga
News headline image
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
From Neumora Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Neumora Therapeutics, Inc. - Common Stock publicly traded?
Yes, Neumora Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Neumora Therapeutics, Inc. - Common Stock trade on?
Neumora Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Neumora Therapeutics, Inc. - Common Stock?
The ticker symbol for Neumora Therapeutics, Inc. - Common Stock is NMRA on the Nasdaq Stock Market
What is the current price of Neumora Therapeutics, Inc. - Common Stock?
The current price of Neumora Therapeutics, Inc. - Common Stock is 2.130
When was Neumora Therapeutics, Inc. - Common Stock last traded?
The last trade of Neumora Therapeutics, Inc. - Common Stock was at 01/27/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story